- Condition: Pancreatic Cancer
Interventions: Drug: FOLFIRINOX; Drug: Capecitabine; Radiation: Proton Radiation; Procedure: Surgery
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Cancer Institute (NCI)
Not yet recruiting - verified May 2012 - Condition: Gastric Carcinoma
Interventions: Drug: Tesetaxel; Drug: Placebo; Drug: Capecitabine
Sponsors: Genta Incorporated; Genta Incorporated
Recruiting - verified April 2012 - Conditions: Pancreatic Cancer; Rectal Cancer
Intervention: Drug: capecitabine +ganetespib
Sponsors: Emory University; Emory University; Synta Pharmaceuticals Corp.
Not yet recruiting - verified March 2012 - Conditions: Gastrinoma; Glucagonoma; Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Recurrent Pancreatic Cancer; Somatostatinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: temozolomide; Biological: bevacizumab
Sponsors: Stanford University; Stanford University; National Cancer Institute (NCI)
Not yet recruiting - verified January 2012 - Conditions: Locally Recurrent Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: NKTR-102; Drug: Treatment of Physician's Choice (TPC)
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified April 2012 - Conditions: Breast Cancer; Gastrointestinal Cancer
Intervention: Behavioral: questionnaire and interview
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012 - Condition: Colorectal Cancer Metastatic
Intervention: Drug: Chemotherapy
Sponsors: University of Florida; University of Florida
Recruiting - verified February 2012 - Condition: Pancreatic Cancer
Interventions: Drug: Gemcitabine; Drug: Taxotere; Drug: Xeloda; Drug: Cisplatin
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified December 2011 - Condition: Subjects With Advanced Solid Tumors (Including, But Not Limited to Gastric, Head and Neck, NSCLC, Colon, Mesothelioma and Triple Negative Breast Cancer).
Interventions: Drug: ABT-700; Drug: ABT-700 plus erlotinib; Drug: ABT-700 plus Oxaliplatin and Capecitabine
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Conditions: Locally Advance Breast Cancer (LABC); Metastatic Breast Cancer (MBC)
Interventions: Drug: BEZ235 + Trastuzumab Phase l/Phase ll); Drug: Lapatinib + Capecitabine (Phase II)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Gastric Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: capecitabine; Drug: cisplatin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Conditions: Estrogen Receptor Positive Tumor; Breast Cancer
Intervention: Drug: E7389 (eribulin mesylate) and capecitabine
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012 - Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: Number 1 - Capecitabine and ruxolitinib; Drug: Number 2 - Capecitabine and placebo
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2012 - Condition: Pancreatic Cancer
Interventions: Drug: Capecitabine; Drug: Hydroxychloroquine; Radiation: Proton Radiation Therapy
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified December 2011 - Condition: Pancreatic Cancer
Interventions: Drug: Gemcitabine; Drug: Capecitabine; Radiation: Stereotactic Body Radiation Therapy (SBRT)
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified August 2011 - Conditions: Colon Cancer; Rectal Cancer
Intervention: Drug: Study Arm only (modified FOLFOX6)
Sponsors: Brown University; Debora G. Isdale; Memorial Hospital of Rhode Island; Rhode Island Hospital; The Miriam Hospital
Recruiting - verified May 2012 - Conditions: Advanced or Metastatic Solid Tumors; Previously Untreated Gastric Cancer
Interventions: Drug: E7050; Drug: cisplatin; Drug: capecitabine
Sponsors: Eisai Inc.; Eisai Inc.; PharmaBio Development Inc.
Recruiting - verified April 2012 - Conditions: Esophageal Cancer; Malignant Neoplasm of Cardio-esophageal Junction of Stomach
Interventions: Drug: Azacitidine; Drug: Azacitidine; Drug: Azacitidine; Drug: Oxaliplatin; Drug: Oxaliplatin; Drug: Epirubicin; Drug: Epirubicin; Drug: Capecitabine; Drug: Capecitabine
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified June 2011 - Conditions: Breast Cancer; Metastatic Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: Ixabepilone; Drug: Capecitabine; Drug: Motesanib
Sponsors: Thomas Jefferson University; Thomas Jefferson University; Susan G. Komen Breast Cancer Foundation; Amgen
Not yet recruiting - verified January 2012 - Condition: Solid Cancers
Interventions: Drug: bevacizumab; Drug: capecitabine; Drug: GDC-0980; Drug: mFOLFOX6
Sponsors: Genentech; Genentech
Recruiting - verified February 2012 - Condition: Metastatic Breast Cancer
Intervention: Drug: TRC105
Sponsors: Tracon Pharmaceuticals Inc.; Tracon Pharmaceuticals Inc.; Roswell Park Cancer Institute; Department of Defense
Recruiting - verified March 2012 - Condition: Solid Tumor
Intervention: Drug: Tesetaxel plus capecitabine
Sponsors: Genta Incorporated; Genta Incorporated
Recruiting - verified March 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: BMK120; Drug: Capecitabine; Drug: BEZ235
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: HER-2 Gene Amplification
Interventions: Drug: Cisplatin, Capecitabine, Trastuzumab and MM-111; Drug: Lapatinib, Trastuzumab and MM-111; Drug: Paclitaxel, Trastuzumab and MM-111
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified March 2012 - Condition: Pancreatic Cancer
Interventions: Biological: ganitumab; Drug: capecitabine; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Adenocarcinoma of the Pancreas; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: dovitinib lactate; Drug: gemcitabine hydrochloride; Drug: capecitabine; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Other: pharmacological study
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Drug: irinotecan hydrochloride; Biological: bevacizumab; Biological: cetuximab; Drug: capecitabine; Genetic: mutation analysis; Genetic: gene expression analysis; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: nucleic acid sequencing; Genetic: protein expression analysis; Genetic: polymerase chain reaction; Genetic: DNA analysis
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Cognitive/Functional Effects; Colorectal Cancer; Neurotoxicity
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified February 2012 - Condition: Head and Neck Cancer
Interventions: Drug: capecitabine; Drug: vorinostat
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Biological: Ramucirumab DP; Biological: IMC-18F1; Drug: Capecitabine
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified May 2012 - Conditions: Advanced Solid Tumors; Locally Advanced or Metastatic Breast or Colorectal Cancer
Intervention: Drug: tivozanib (AV-951) and capecitabine (Xeloda®)
Sponsors: AVEO Pharmaceuticals, Inc.; AVEO Pharmaceuticals, Inc.
Recruiting - verified October 2011 - Condition: Metastatic Breast Cancer
Interventions: Drug: Eniluracil; Drug: 5-Fluorouracil; Drug: Leucovorin; Drug: Capecitabine
Sponsors: Adherex Technologies, Inc.; Adherex Technologies, Inc.
Recruiting - verified August 2011 - Condition: Metastatic or Unresectable Solid Tumor Malignancy
Interventions: Drug: Capecitabine; Drug: Hsp90 Inhibitor AUY 922
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Novartis Pharmaceuticals
Recruiting - verified November 2011 - Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified April 2012 - Condition: Advanced Cancers
Interventions: Drug: Oxaliplatin; Drug: Capecitabine; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Gastrointestinal Cancer
Interventions: Drug: Capecitabine; Drug: Oxaliplatin; Drug: Panitumumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Amgen
Recruiting - verified May 2012 - Condition: Gastrointestinal Cancers
Interventions: Drug: Capecitabine; Drug: Oxaliplatin; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified March 2012 - Condition: Colorectal Cancer
Interventions: Drug: Azacitidine; Drug: Capecitabine; Drug: Oxaliplatin; Drug: Azacitidine MTD
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified March 2012 - CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric CancerConditions: Esophageal Cancer; Gastric Cancer
Interventions: Drug: bevacizumab; Drug: trastuzumab; Drug: oxaliplatin; Drug: capecitabine
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; Genentech
Recruiting - verified September 2011 - Conditions: Cholangiocarcinoma; Hepatobiliary Neoplasm; Liver Cancer; Bile Duct Cancer; Cancer of Gallbladder
Interventions: Procedure: Stereotactic Body Radiotherapy; Drug: Gemcitabine100 mg/m2; Drug: Cisplatin; Drug: Carboplatin; Drug: Capecitabine; Drug: 5FU
Sponsors: Stanford University; Stanford University
Recruiting - verified June 2011 - Condition: Non-Metastatic Adenocarcinoma of the Rectum
Interventions: Procedure: Radiation Therapy; Drug: Capecitabine; Drug: AZD6244
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: carboplatin; Drug: oxaliplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: University College, London; University College, London; National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified December 2011 - Conditions: Pancreatic Cancer Stage II; Pancreatic Cancer Stage III
Interventions: Drug: Neoadjuvant gemcitabine, capecitabine, and docetaxel; Drug: Gemcitabine, capecitabine, docetaxel followed by radiotherapy
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011 - Condition: Carcinoma
Interventions: Drug: Intraperitoneal Oxaliplatin; Drug: Intraperitoneal Oxaliplatin; Drug: Intraperitoneal Oxaliplatin; Drug: Intraperitoneal Oxaliplatin; Drug: Intraperitoneal Oxaliplatin
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified December 2011 - Condition: Rectal Neoplasms
Intervention: Other: 5 days of radiation followed by FOLFOX chemotherapy given every other week for 6 weeks
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified January 2012 - Condition: Advanced Solid Tumors
Intervention: Drug: Temsirolimus and capecitabine
Sponsors: Georgetown University; Georgetown University; Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting - verified April 2012 - Conditions: Head and Neck Cancer; Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Stage IV Salivary Gland Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions: Drug: lapatinib ditosylate; Drug: capecitabine
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012 - Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Cholangiocarcinoma
Intervention: Drug: Gemcitabine, Capecitabine and Bevacizumab
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; Genentech
Recruiting - verified December 2011 - Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: XELOX regimen; Drug: hydroxychloroquine
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Pancreatic Cancer; Periampullary Adenocarcinoma
Interventions: Drug: capecitabine; Drug: vorinostat; Radiation: Radiotherapy; Procedure: Surgery to remove tumor
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI); National Comprehensive Cancer Network
Recruiting - verified January 2012 - Condition: Breast Cancer
Intervention: Drug: Capecitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012 - Condition: Pancreatic Cancer
Interventions: Drug: Erlotinib; Drug: capecitabine; Radiation: Radiation Therapy; Drug: gemcitabine; Drug: erlotinib
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; Genentech
Recruiting - verified April 2012 - Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
Interventions: Drug: capecitabine; Drug: docetaxel; Drug: fluorouracil; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Radiation: Radiation Therapy; Drug: Capecitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012 - Conditions: Stomach Neoplasms; Esophageal Neoplasms
Interventions: Drug: BMS-833923; Drug: Cisplatin; Drug: Capecitabine
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Recruiting - verified June 2011 - Condition: Pancreatic Cancer
Interventions: Radiation: Accelerated Short Course Radiation; Drug: Capecitabine
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital
Recruiting - verified October 2011 - Condition: Pancreas Cancer
Intervention: Drug: Lapatinib and Capecitabine
Sponsors: Georgetown University; Georgetown University; GlaxoSmithKline
Recruiting - verified October 2011 - Condition: Neuroendocrine Tumors
Intervention: Drug: Capecitabine and temozolomide
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011 - Condition: Pancreatic Cancer
Intervention: Drug: Gemcitabine (Gemzar), docetaxel (Taxotere), and capecitabine (Xeloda)
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011 - Condition: Pancreatic Cancer Stage IVA
Interventions: Drug: Gemcitabine, docetaxel, and capecitabine; Radiation: Radiation therapy with gemcitabine
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: lapatinib; Drug: capecitabine [Xeloda]
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Conditions: Metastatic Breast Cancer; Metastases, Brain
Interventions: Drug: capecitabine; Drug: lapatinib; Drug: trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Breast Cancer; Breast Neoplasms; Breast Tumors; Cancer; Locally Recurrent and Metastatic Breast Cancer; Metastases; Metastatic Cancer; Oncology; Solid Tumors; Tumors
Interventions: Drug: AMG 386 15 mg/kg, Capecitabine and Lapatinib; Drug: AMG 386 15mg/kg, Paclitaxel and Trastuzumab; Drug: AMG 386 30 mg/kg, Paclitaxel and Trastuzumab; Drug: AMG 386 30 mg/kg, Capecitabine and Lapatinib; Drug: AMG 386 10 mgkg, Paclitaxel and Trastuzumab; Drug: AMG 386 10 mg/kg, Capecitabine and Lapatinib
Sponsors: Amgen; Amgen
Recruiting - verified March 2012 - Condition: Advanced Cancer
Interventions: Drug: Capecitabine; Drug: Doxorubicin; Drug: Ixabepilone; Drug: Docetaxel; Drug: Paclitaxel; Drug: Brivanib alaninate
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Conditions: Breast Cancer; Metastatic Cancer
Interventions: Drug: capecitabine; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Drug: lapatinib ditosylate; Drug: paclitaxel; Drug: vinorelbine ditartrate; Drug: Trastuzumab
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; Department of Defense; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Solid Tumors; Neoplasms, Breast; Cancer
Interventions: Drug: Lapatinib in combination with an anti-cancer agent; Drug: Lapatinib; Drug: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: Stomach Cancer; Gastric (Stomach) Cancer; Neoplasm of Cardioesophageal Junction; Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: bevacizumab; Drug: carboplatin; Drug: capecitabine
Sponsors: Stanford University; Pamela L. Kunz; Genentech
Recruiting - verified February 2012 - Condition: Pancreatic Cancer
Intervention: Radiation: Proton Therapy, Capecitabine, Gemcitabine
Sponsors: University of Florida; University of Florida
Recruiting - verified May 2012 - Condition: Pancreatic Cancer
Interventions: Biological: GVAX pancreatic cancer vaccine; Drug: cyclophosphamide
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Drug: capecitabine; Drug: oxaliplatin; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Procedure: neoadjuvant therapy; Procedure: therapeutic surgical procedure; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Pancreatic Cancer
Intervention: Other: Capecitabine, proton, Gemcitabine
Sponsors: University of Florida; University of Florida
Recruiting - verified March 2012 - Conditions: Adenocarcinoma of the Pancreas; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: docetaxel; Drug: capecitabine; Radiation: intensity-modulated radiation therapy; Drug: oxaliplatin; Procedure: pancreatic surgical procedure; Procedure: therapeutic conventional surgery
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Pancreatic Cancer
Interventions: Drug: Bevacizumab; Drug: Erlotinib; Drug: Capecitabine; Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified May 2012 - Condition: Metastatic Liver Cancer
Interventions: Device: Sir-Spheres; Drug: Capecitabine
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center; Sirtex Medical
Recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Drug: sunitinib; Drug: capecitabine; Radiation: WBRT
Sponsors: Baylor Breast Care Center; Baylor Breast Care Center
Recruiting - verified January 2012 - Conditions: Esophageal Neoplasms; Stomach Neoplasms; Neoplasm Metastasis
Intervention: Drug: capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
Sponsors: Duke University; Duke University; Hoffmann-La Roche; Sanofi-Aventis; Genentech
Recruiting - verified December 2011 - Condition: Neoplasms, Breast
Intervention: Drug: lapatinib + capecitabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Cholangiocarcinoma
Intervention: Other: Observation data collection study.
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified September 2011 - Condition: Colorectal Cancer
Interventions: Drug: capecitabine; Drug: 5-fluorouracil; Procedure: Surgical Resection; Radiation: Radiation therapy
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Rectal Cancer
Intervention: Drug: Oxaliplatin, Capecitabine, Celecoxib with Radiation
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance
Recruiting - verified December 2011 - Condition: Kidney Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Weill Medical College of Cornell University; National Cancer Institute (NCI)
Recruiting - verified June 2009
 |
Capecitabine Clinical Trials |
